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Glucose-6-phosphate Dehydrogenase Deficiency: A Review 
Nidhruv Ravikumar,1 Graeme Greenfield.2 
Abstract 
Deficiency of the glucose-6-phosphate dehydrogenase (G6PD) enzyme is a common X-linked disorder that affects people globally. It was first identified in 
the 1950s as a disorder that primarily affects the red blood cells, causing a myriad of symptoms including acute hemolytic anemia, neonatal jaundice and 
chronic nonspherocytic hemolytic anemia. This deficiency has been extensively studied and, especially within the last 5 years, there have been 
improvements in the diagnosis and management. Various methods of diagnosis exist; however, recent research focuses on the use of biosensors for a 
more accurate and less time-consuming diagnosis. Guidelines suggest controlling symptomology, as no specific treatment currently exists. A common 
complication of the disease is neonatal jaundice, and research on phototherapy has proved to show some effect in managing this condition. In the last 
year, protein-protein interactions have been used as targets to enhance enzyme stability and activity. AG1 is a small molecule activator that has 
demonstrated effectiveness in treating G6PD deficiency in models. This review summarizes existing literature and potential areas of research on glucose-
6-phosphate dehydrogenase deficiency including clinical characteristics, diagnosis, and management.  
 




Glucose-6-phosphate dehydrogenase (G6PD) deficiency is one of the 
commonest forms of enzymatic disorders affecting humans worldwide. 
Four-hundred million people across the globe are estimated to be 
affected, with the highest prevalence being in those of African, Asian 
and Mediterranean descent.1,2 G6PD is an enzyme in the pentose 
phosphate pathway (PPP) that catalyzes the first step.3 PPP plays a role 
in reductive biosynthesis, cell proliferation and processing of 
antioxidants. The products of this pathway are important in nucleotide 
synthesis, lipogenesis, cholesterol synthesis and glutathione reduction. 
Disruption of the PPP will lead to a generation of free radicals that 
cause oxidative damage to red blood cells (RBCs) and, in turn, 
hemolysis (breakdown of RBCs).4  
 
G6PD deficiency was first identified in the 1950s a small number of 
American soldiers who developed a hemolytic anemia upon exposure 
to anti-malarial drugs. In later years, the genetic cause of the disease 
was identified and was attributed to mutations in the g6pdx gene 
located on the X chromosome.5 Since the gene is located on the X 
chromosome, it is inherited in a sex-linked manner (Figure 1). Males 
have only one copy of the X chromosome; hence, those who inherit the 
mutation are considered hemizygous and will develop the condition. 
However, females can be either homozygous (two pairs of mutant 
alleles) or heterozygous (only one mutant allele). Homozygous females 
will be G6PD deficient, while heterozygous females will be carriers. 
Carriers are not usually affected by the condition and rarely present 
with symptoms.3 The majority of the population with the deficiency, 
mainly males, do not develop symptoms unless they are exposed to 
certain oxidative stressors (i.e., fava beans), oxidative medications (i.e, 
antimalarial agents) and infections.3,5 The geographical distribution of 
the condition is similar to sickle cell anemia and thalassemia, and 
corresponds to the global distribution of malaria. This has led to the 
hypothesis that G6PD deficiency offers some protection against the 
parasite Plasmodium falciparum, a cause of malaria.6 This review thus 
seeks to evaluate existing literature regarding the pathophysiology, 
diagnosis, and management of G6PD deficiency, and provide insight 
into potential areas for further research. 
 





Search Strategy and Selection Criteria 
A comprehensive literature search was performed through PubMed 
resources to identify the articles which discussed the prevalence, 
pathophysiology, diagnosis and management of G6PD deficiency. 
Keywords used includeed ‘Glucose-6-phosphate dehydrogenase 
deficiency’ or ‘G6PD deficiency’, ‘Favism’ and ‘Congenital hemolytic 
anemia’. The search terms were used as keywords and in combination 
as MeSH terms to maximize the output from literature findings. In 
conjunction to this, a manual search of reviews and other relevant 
studies was conducted. A staged literature search was done, whereby  
Review  
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Figure 2. Regional prevalence estimates of G6PD deficiency (Data collected 
from: Nkhoma E, Poole C, Vannappagari V, Hall S, Beutler E. The global 
prevalence of glucose-6-phosphate dehydrogenase deficiency: A systematic 




a separate literature search was performed for each section within this 
article and all the relevant studies were identified and summarized 
separately. The relevant articles are cited and referenced within each 




It is estimated by The National Organization for Rare Disorders that 
there are four hundred million people who are living with G6PD 
deficiency. An estimate suggests that approximately 8% of the world’s 
population carry the alleles responsible for the development of G6PD 
deficiency, ranging from a maximum of 35% in regions of Asia to 0.1% 
in Japan and certain parts of Europe, which makes it a significant public 
health problem.7 It is observed to have higher prevalence in Asia, the 
Middle East, Latin America and the Mediterranean (Figure 2).1 Since the 
mode of inheritance is X-linked, males seem to be more affected, 
compared to females; however, the most common genotype is a 
heterozygous female.3 In the past it was noted that there was an 
increased prevalence of the disease in high-risk countries which often 
correlated to the demographics observed with malaria. However, in 
recent times due to significant globalization and the accompanying 
migration of individuals, there has been a considerable change in 
population demographics. Hence, in the majority of countries, there 
exists pockets of population groups that are affected by the disorder, 
causing an increase in prevalence of this disorder in countries where it 
would be considered rare in the past.9 In the United States, for instance, 
people of African-American descent are observed to be predominantly 
affected by the disorder. In recent years, the frequency of the affected 
population is as high as about 10-14%.1  
 
The high prevalence of the condition increases its probability of being 
associated with other pathological conditions, particularly those 
affecting RBCs (sickle cell hemoglobinopathy and thalassemia).5 
 
Pathophysiology 
Pharmacogenetics is the process in which the genetic determinants of 
an individual’s response to drugs are measured. In fact, G6PD 
deficiency was discovered using this technique. In the 1950s, 
primaquine, an antimalarial drug, was produced in large-scale when 
the US military was deployed to areas endemic to malaria. The army 
physicians observed that, apart from the predicted side effects of 
gastrointestinal complaints, some soldiers developed jaundice and 
anemia. This toxic side effect was then termed as primaquine 
sensitivity syndrome. In the years following, Brewer et al.,10 tested the 
effects of primaquine on human volunteers, which provided valuable 
insight into the mechanism of the condition, despite its lack of ethical 
compliance. The group conducted enzymatic analysis and concluded 
that there was a marked reduction in the levels of the G6PD enzyme in 
the RBCs of primaquine-sensitive patients, thus coining the term G6PD 
deficiency. Further genetic analysis of the condition revealed that the 
gene coding for the enzyme is located on the X chromosome, prompting 
an X-linked inheritance pattern.11 Prior to this discovery, favism was a 
well-known condition that caused similar symptoms in certain populations 
upon consumption of fava beans. It was later concluded that the 
underlying biochemical effect was the same as that caused by primaquine. 
 
In a G6PD-deficient person, no abnormalities are observed in the steady 
state. This comes down to the role of G6PD in the RBCs.11 It is an enzyme 
present in the cytosol that is involved in the PPP by controlling the 
entry of glucose-6-phosphate (G6P) into the pathway. G6PD oxidizes 
G6P to 6-phosphogluconolactone and, in the process, reduces NADP+ to 
NADPH (Figure 3).12 Hence, its main role is to provide reductive potential 
by the production of NADPH.11 This reaction is the rate determining step 
of the pathway, and therefore, decreased activity of G6PD causes 
reduced levels of NADPH.12 NADPH is a key reductive agent that 
maintains glutathione in its reduced state (Figure 3). Glutathione in its 
reduced form is important in scavenging potentially harmful reactive 
oxygen species (ROS) and confers vital protection to RBCs.13 Excess ROS 
have detrimental effects on the cell function –causing an increase in 
erythrocyte membrane fragility leading to hemolysis, release of 
hemoglobin into the plasma and systemic nitric oxide scavenging 
leading to vasoconstriction.13 This is caused by its interference in 
reactions involving proteins, nucleotides and lipids.12  
 
Figure 3. Oxidative stage of Pentose Phosphate Pathway (PPP) indicating 
deficiency of Glucose-6-phosphate dehydrogenase leads to decreased 
NADPH levels. In the glutathione reduction pathway, decreased NADPH 
causes accumulation of GSSG (oxidized glutathione), that prevents the 




Although G6PD deficiency affects every cell of the body, its primary 
effects are blood related, as RBCs do not have an alternate source of 
NADPH. Non-RBC cells, on the other hand, have other non-specific 
enzymes (hexose-6-phosphate dehydrogenase) that work in a similar 
way to G6PD to generate NADPH. In the steady state, the levels of NADPH 
in the RBCs are adequate. However, exposure to oxidative stressors 
poses a challenge to G6PD-deficient RBCs, due to the generation of 
excess ROS.11 This leads to the lysis of RBCs, causing hemolytic 
anemia.13 As with other RBC enzymes, the activity of G6PD reduces as 
the cell ages. This is not endangering in G6PD-normal red cells; 
however, in G6PD-deficient cells, the older RBCs have lower levels of 
the enzyme, as compared to the younger cells. This then correlates to 
the reduced RBCs life span and acute haemolysis.7 A classification 
system can thus be formulated based on the variation in enzyme 
activity levels.  
 
Classification of G6PD Deficiency 
The level of disease severity varies depending on residual enzyme 
activity and substrate binding, which are influenced by the type of 
mutation.13 The World Health Organization (WHO)7 categorizes the 
disease into the following 5 classes:  
 Class I (very severe deficiency): less than 1% G6PD activity 
and is commonly caused by the Mediterranean mutation 
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 Class III (moderate deficiency): 10% to 60% activity of G6PD 
 Class IV (normal): G6PD activity is between 60% and 150%.  
 Class V: G6PD activity is greater than 150%  
 
A- and Med are common alleles that cause moderate to mild severe 
deficiency and they belong to class II and III. Patients affected by the 
A+ and B variants fall under class IV and class V. Most people affected 
by the deficiency fall in Class II and III, i.e., moderate deficiency and 
have fewer problems.7,10 The symptoms observed and prevalence of 
each class is summarized in Table 1. 
 
Genetics  
The gene that codes for G6PD, g6pdx, is situated proximal to the 
telomeric end of the distal arm (q arm) at band 28 of the X chromosome 
in humans (Xq28) (Figure 4).7,14-15 This gene has 13 exons and 12 introns, 
spans 18.5 Kilobases, and has a GC rich promoter region that encodes 
a product of 1545 bp.2,16,17 It has a high rate of heterogeneity, and over 
300 variants have been found. Only 217 precise mutations, however, 
are currently known.1,11,14,18 Majority of the mutations observed are 
point mutations that occur in the coding DNA, introns and 5’ and 3’ 
untranslated regions.14 S188F (Mediterranean mutation) in the Arab 
population, C131G and G487A in Bangladesh, and A376G in North 
America, Africa, Yemen and Saudi Arabia are the commonest mutations 
discovered in G6PD-deficient patients.2,19-21 These variants can be either 
polymorphisms, with milder clinical signs, or sporadic variants. The 
frequency of variant polymorphs is higher than sporadic variants, 50% 
to 1% respectively. Nevertheless, the frequencies of sporadic variants 
have reached polymorphic frequencies, due to some protection offered 
against malaria caused by Plasmodium falciparum.  
 
All mutations cause a decrease in enzyme stability.14 Active G6PD 
enzyme occurs as a homodimer or homotetramer. The majority of the 
mutations in the gene cause a change in the amino acid sequence of 
the enzyme, thus decreasing stability. The postulated mechanism for 
this decrease in stability is disturbance in protein folding. This affects 
particularly the dimer interface, causing a disturbance in effective 
dimerization. Moreover, it was also observed that a structural NADP 
molecule is an essential moiety that maintains the structural integrity 
of the enzyme. Mutations that alter the binding of this structural NADP 
molecule also contribute to the decrease in stability of the enzyme.5  
 
Males are predominantly affected, as the gene is present on the X 
chromosome. They can be either hemizygous normal or hemizygous 
deficient. In contrast, females can be homozygous normal, homozygous 
deficient or heterozygous. A mosaic pattern of the wild type and the 
deficient variant is observed in heterozygous females, caused by X 
chromosome inactivation (i.e., lyonization). This leads to the presence 
of differing levels of normal and deficient RBCs. Due to the random 
nature of this phenomenon, the proportions of deficient variant vary, 
resulting in a spectrum of symptomology.16 If the proportion of deficient 
RBCs is greater than 50% in heterozygous females, they become more 
susceptible to hemolysis, but with less severity when compared to 
homozygous deficient females and hemizygous deficient males. 
 
Clinical Manifestation 
The majority of the population with a polymorphic G6PD gene does not 
manifest any clinical symptoms. In fact, with sporadic variants, the 
chance of developing acute hemolysis is 1 in 106, which is particularly 
infrequent.5 For the greater part of their lifespan, people with the 
disease are asymptomatic; however, symptoms manifest when the 
body is subjected to oxidative stress. The most common stressors 
include medications and infection, while diabetic ketoacidosis (DKA) is 
also a precipitator in certain variants.2 Although the mechanism of 
action of DKA is not known, the increased risk of infection that 
accompanies DKA is postulated to link DKA with specific variants of G6PD 
deficiency.3  
 




Figure 4. g6pdx Gene Located on the Telomeric End of the q Arm at Band 28 
of the X Chromosome (Xq28).  
 
 
Typically, G6PD deficiency presents as acute hemolytic anemia, chronic 
nonspherocytic hemolytic anemia, neonatal jaundice and favism.5 The 
most common presentation is acute hemolytic anemia, with symptoms 
of anemia, fatigue, back or abdominal pain, jaundice and 
hemoglobinuria occurring promptly after exposure to an oxidative 
stress. Hemolytic anemia is characterized by premature lysis of RBCs.3 
Due to the polymorphic character of G6PD deficiency, a number of 
clinical presentations are observed in different individuals. Different 
mutations in the gene lead to variable severity and the associated 
symptoms tend to vary in a similar fashion. For instance, people with 
the Mediterranean mutation often fall under Class I and develop very severe 
clinical signs such as chronic nonspherocytic hemolytic anemia (CNSHA).5 
 
An important complication of G6PD-deficiency is neonatal jaundice, 
which can occur in neonates 2 to 3 days after birth with varying 
severity. Neonates with the G6PD mutation also inherit a variant allele 
for uridine-diphosphate-glucuronosyltransferase 1 (UGT1A1).16 This 
mutation is responsible for Gilbert syndrome, where the conjugation of 
bile and glucuronic acid is impaired, leading to a condition where the 
levels of bile in the body are very high (i.e., hyperbilirubinemia).5,16 This 
increases the risk of babies developing jaundice. If hyperbilirubinemia 
is not treated effectively, bilirubin encephalopathy (kernicterus) can 
result and potentially leave the neonate with permanent neurological 
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Favism is another precipitating disorder in individuals with G6PD 
deficiency. The compounds innately present in fava beans, divicine, 
and isouramil, are strong oxidizing agents, thereby placing the cells 
under oxidative stress. In addition, neonates exposed to fava beans, 
through breast milk or passively, can soon develop neonatal jaundice.16  
 
In males with the rare G6PD sporadic variants with severe deficient 
function, chronic nonspherocytic hemolytic anemia (CNHSA) is a 
recognized complication. This occurs when there is a lack of NADPH in 
the steady state for maintaining the levels of oxidizing agents. The 
excess build-up of oxidizing agents in the cell damages the RBC 
membrane, resulting in reduced RBC lifespan and chronic haemolysis.5  
 
Differential Diagnosis  
A variety of different disease processes often clinically manifest in a 
similar fashion to that of G6PD deficiency, characterized primarily by 
hemolytic anemia. Therefore, it is important to consider the following 
diseases in the differential diagnosis:1 
 Acquired autoimmune hemolytic anemia  
 Pyruvate kinase deficiency  
 Cold antibody hemolytic anemia  
 Hereditary spherocytosis  
 Sickle cell anemia  
 Thalassemia  
 Bilirubin conjugation disorders (i.e., Gilbert Syndrome) 
 Hemolytic disease of the newborn (Erythroblastosis fetalis) 
 Methemoglobinemia 
 Acquired conditions (i.e., Black Water Fever, Clostridium 




In order to prevent the occurrence of hemolytic episodes, the presence 
of G6PD-deficiency should always be considered in populations of high-
risk background, including people of African, Asian or Mediterranean 
descent. It is important to note that screening for the deficiency needs 
to be performed in such individuals prior to commencement of any 
treatment that may induce an oxidative stress. Although people 
carrying the variant allele for the disorder are usually asymptomatic, 
the influence of a particular oxidative stressor may prove to be fatal. 
Hence the deficiency should be considered, especially in those with a 
family history of recurrent jaundice, splenomegaly, cholelithiasis, or 
anemia. Individuals who experience hemolytic anemia after exposure 
to a known oxidative stressor, those with characteristic blood film 
findings and neonates who have jaundice should also be considered 
for diagnostic testing of G6PD deficiency.3 
 
Different methods of diagnosis can be used. Clinically, quantitative 
measurement of the enzyme function provides the required 
information to classify G6PD-deficiency.22 The most widely used tests 
are the fluorescent spot test (FST) and the quantitative 
spectrophotometric assay, both of which rely on the principle of 
conversion of NADP+ to NADPH.5 Identification of the genetic mutations 
through molecular analysis can confirm the exact underlying genetic 
defect.3  
 
The FST is the first line diagnostic tool that is used in patients suspected 
with G6PD deficiency.14,22 It is a quick and inexpensive test that is often 
used in regions where the deficiency and malaria are more prevalent, 
ensuring that the patient will not experience hemolytic anemia upon 
exposure to antimalarial drugs.5 Although inexpensive, FST requires the 
use of special equipment like UV light, a water bath or heat block, and 
a dark room.3 To combat the difficulty of accessing special equipment, 
researchers recently developed new techniques that do not require 
such apparatus.5 The formazan-based spot test is the most commonly 
used method, which can detect less than 50% of normal G6PD activity.3 
The formazan method uses a substrate of 3-(4,5-Dimethylazolyl-2)-2,5-
diphenyltetrazolium bromide (MTT) and a hydrogen carrier, phenazine 
methosulphate (PMS). A formazan substrate is formed from these 
substrates under the influence of the NADPH that G6PD produces. New 
studies have demonstrated that the water-insoluble formazan is formed 
by MTT, therefore making the quantitative analysis of G6PD activity 
difficult. Tantular and Kawamoto23 have now discovered a new 
formazan substrate, 2-(2-methoxy-4-nitrphenyl)-3-(4-nitrophenyl)-5-
(2,4-disulphophenyl)-2H tetrazolium monosodium salt (WST-8), that 
does not react with hemoglobin and is water soluble. They have proved 
that the WST-8 formazan-based spot test is a less time consuming and 
more accurate method of detecting G6PD deficiency.23  
 
At the laboratory level, the spectrophotometric assay is the gold 
standard in diagnosing the deficiency. It uses the hemolysate of blood 
(resulting product from the lysis of RBCs) to detect the total enzymatic 
activity. Enzyme activity is measured as a change in the absorbance at 
340 nm at a given temperature, for a given hemoglobin concentration 
(unit of enzyme per grams of hemoglobin; IU/gHb) or, in rare cases, for 
a given number of RBCs (unit of enzyme per RBC; U/RBC).24 Normal 
activity is considered to be 7 to 10 IU/gHb.3 This technique is dependent 
on the concentration of hemoglobin in the blood. A disruption in the 
levels of hemoglobin can therefore lead to abnormal results. In 
individuals with anemia or iron deficiency, the G6PD activity will be 
falsely elevated.24  
 
Due to the disparities in enzyme activity through spectrophotometric 
assay measurement, recent studies have focused on flow cytometry as 
an alternative option.24 Earlier models of flow cytometry exploited the 
capacity of G6PD to reduce oxidized methaemoglobin (MetHb) to normal 
hemoglobin. Newer models are based on the capacity of G6PD to reduce 
MTT insoluble tetrazolium salts.24 The principle behind flow cytometry 
corresponds to the light scattering ability of the moving particles and 
fluorescence emission. Fluorescence emission is the primary property 
that is measured in determining the levels of G6PD.25 Tetrazolium salts 
are stained with a fluorescent dye.24 The levels of the enzyme are 
directly proportional to the amount of fluorescent probe bound to the 
salt.25 This is a laborious process and requires several hours for processing 
the sample and staining it. Nowadays, however, a simpler and quicker 
flow cytometric assay using the same principle has been developed.24  
 
A study conducted by Bancone et al.,26 has shown that the flow 
cytometric assay and spectrophotometric assay are equally reliable for 
the diagnosis of G6PD deficiency in patients with normal hemoglobin 
and without anemia. However, they proved that flow cytometric assay 
is the tool of choice in anemic patients and those with other 
haemoglobinopathies, as it is not influenced by hemoglobin 
concentration. 
 
The spectrophotometric assay for G6PD-deficiency testing is fairly 
expensive and requires skilled operators, an equipped laboratory and 
a reliable source of material. Ironically, these are available in hospitals 
only and are inaccessible in tropical countries, where the disease is 
highly prevalent.26 Point-of-care rapid diagnostic tests (POC RDT) is now 
considered a relatively inexpensive diagnostic tool. It is a quantitative 
test, and the most commonly used ones are BinaxNOW and CareStart.3 
These devices are biosensors and have been developed in recent years 
to provide a more accurate diagnosis.26 The activity of G6PD can be 
obtained quantitatively in 4 minutes by these handheld devices to 
devise a suitable treatment plan.27 In a study comparing the diagnostic 
power of CareStart and spectrophotometric assay, it was demonstrated 
that CareStart has a higher diagnostic power, with appreciable 
sensitivity and specificity.26 Even though technicians easily operated 
CareStart, certain changes in the model were required to make it more 
user-friendly.26 With improvements, POC RDTs shall be used more often 
in detecting G6PD deficiency.  
 
The timing of quantitative assay is crucial, as this can influence the 
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bone marrow response falsely elevates the levels of the enzyme, due 
to consequent reticulocytosis. Therefore, measurement at the steady 
state is important. 
 
The aforementioned techniques are useful and accurate in the 
detection of homozygous males and females, yet they fail to diagnose 
accurately in heterozygous females with intermediate enzyme activity 
(due to lyonization).5 In these cases, an accurate diagnosis can be 
made by molecular analysis methods. Molecular analysis involves 
sequencing the g6pdx gene to detect known mutations that cause the 
disease.3 Different methods have been employed for the simple 
detection of the common mutations. Classical molecular techniques 
include restriction enzyme analysis (PCR-RFLP), amplification refractory 
mutation system (ARMS), gradient gel electrophoresis (DGGE), 
denaturing high-performance liquid chromatography (DHPLC), probe 
melting curve and reverse dot blot assay.28  
 
Management and Prevention 
Once the diagnosis of G6PD deficiency is made, the most important next 
step is to discontinue the use of the offending oxidative stressor, most 
commonly a medication. Most patients recover spontaneously but 
should undergo careful monitoring. Bone marrow function in these 
patients tends to be normal; hence, they respond by increasing the 
production of RBCs. This causes a reduction in age of the circulating 
RBCs, making them less susceptible to hemolysis. This process plays a 
role in the self-limiting nature of the deficiency, thus limiting the need 
for management.  
 
However, there are circumstances that require management. Firstly, if 
the anemia caused by the stressor is very severe, then a blood 
transfusion can be lifesaving. Anemia can be severe if the patient had 
pre-existing anemia, or if the stressor caused a rapid decline in the 
level of hemoglobin. There are no consensus guidelines on the use of 
transfusion in acute hemolytic anemia caused by G6PD. One proposal 
put forth by Luzzatto et al.,11 suggests that if the level of hemoglobin 
is less than 70 g/L, consideration should be given to a blood 
transfusion. If hemoglobin is less than 90 g/L, and there are signs of 
significant hemolysis (hemoglobinuria), then immediate blood 
transfusion should again be considered. If there are no signs of 
hemoglobinuria, blood transfusion is not necessary, rather the patient 
should be monitored closely for 48 hours.11 Consideration of co-
morbidities, hemodynamic stability and the patients previous hemolytic 
experience may help guide the decision to initiate transfusion.  
 
Acute kidney injury is a possible complication that occurs with severe 
acute hemolytic anemia. This is due to a situation, such as in the case 
of hypovolemic shock, and not because of damage caused by 
hemoglobinuria. Renal function usually recovers with time; however, 
the patient needs to be put on hemodialysis in some cases.11  
 
Moreover, in children with severe anemia, administration of oxygen and 
fluids is critical. They might also need to have healthy blood cells 
transfused.29 There are no specific treatments for the management of 
G6PD deficiency, rather avoiding the oxidative stressor is the 
recommended management plan.  
 
Patient education about avoiding the triggers and recognition of signs 
and symptoms is critical in the management of the deficiency and to 
prevent further exacerbations. This is particularly important in patients 
with severe deficiency and lower enzymatic activity. Advice regarding 
diet and lifestyle modifications are usually given to the patient to 
prevent complications.9  
 
Phototherapy 
Neonatal jaundice is a common condition that occurs in children that 
are affected with G6PD deficiency. In order to manage this condition, 
phototherapy is a technique that is often used.30 The probability pf 
developing severe hyperbilirubinemia is a deciding factor for the 
initiation of phototherapy. An increased risk of brain damage due to 
hyperbilirubinemia is present in G6PD deficiency, thus potentiating the 
need for phototherapy in the management of neonatal jaundice.31 
Phototherapy is a technique that uses visible light in the treatment of 
hyperbilirubinemia in neonates. This intervention involves reducing 
serum bilirubin by transforming it into water soluble isomers.32 It is 
traditionally provided by fluorescent lamps, with radiance of 296 
µ𝑤/𝑐𝑚  in the 400-480 nm range and 250 µ𝑤/𝑐𝑚  in the 425-475 nm 
range, directly on the infant’s skin. Phototherapy has been proved to 
be effective in prophylaxis along with management of neonatal 
jaundice.30 It may be used often, however, in certain cases where the 
adverse reactions caused are detrimental. It can cause acute side 
effects, including interference in the mother-child relationship, thermal 
and hydro-electrolytic imbalance, skin lesions and bronze baby 
syndrome, in addition to late side effects.31,33 
 
Side Effects  
Interference in the Mother-Child Relationship 
The nature of the treatment is such that the neonate has to be 
separated from the mother for a period of time, thus limiting skin-skin 
contact and breastfeeding.31 Moreover, there exists an increased risk of 
vulnerable child syndrome, wherein parental reactions to a life-threatening 
illness can cause long-term psychological effects on the children.  
 
Thermal and Hydro-Electric Imbalance 
A change in the thermal environment occurs within the neonate upon 
initiation of phototherapy. Subsequently, insensible water loss, 
hypothermia or hyperthermia and dehydration are potential side effects 
that may occur. It has also been noted that there exists reduced 
absorption of water, sodium and potassium. However, this is often 
transient, and resolves upon discontinuation of the treatment. 
Dehydration is seen as a serious complication, and thus in order to 
prevent dehydration during the course of the treatment, it is 
recommended to increase water supply by 10 to 15 ml/kg/day.31 
 
Calcium levels are also closely monitored in neonates on phototherapy, 
due to an increase in urinary calcium excretion. Moreover, light affects 
calcium homeostasis by inhibiting melatonin secretion from the pineal 
gland leading to hypocalcaemia. The levels of calcium tend to return to 
normal within 24 hours after ending the treatment.34 
 
Skin lesions  
Macules, papules and a maculopapular rash may often be caused as a 
consequence of phototherapy. In cases of haemolytic disease, such as 
G6PD-deficiency, an increased risk of purpuric eruption exists, due to 
simultaneous transfusion of blood and intravenous immunoglobulins.31  
Phototherapy also poses an increased occurrence of common and 
atypical nevi as was demonstrated by Csoma et al.35 
 
Neoplasms 
There were multiple in vitro studies that were conducted on the risk of 
phototherapy causing subclinical carcinogenic risk hypothesising that a 
wavelength of 400-450 nm would pose a problem in phototherapy.36-39 
This was thought as it induces photosensitization of riboflavin which is 
an endogenous substance. However, this was proved wrong by a group 
of researchers who demonstrated the shielding effect of the Soret band 
of haemoglobin at wavelengths of 400-500 nm.33 There were 2 studies 
conducted by the same group of researchers to demonstrate the risk 
of developing cancer with phototherapy. Both studies demonstrated 
that relative risk of developing cancer with phototherapy is statistically 
insignificant.40,41 With the control of confounding variables, the association 
of cancer and phototherapy can be eliminated, but due to the possibility 
of partial causality, the use of phototherapy should be controlled.41 
 
Bronzed Baby Syndrome 
Phototherapy is also known to cause bronze baby syndrome (BBS) in 
certain neonates. This is an uncommon alteration in the colour of the 
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skin (dyschromia) that occurs as a consequence of phototherapy.42 
Kopelman et al., reported the first case of BBS in 1972.43 Increased 
accumulation of photoisomers of bilirubin, metabolic precursors or 
degradation products, or copper-porphyrin conjugates is the proposed 
cause of BBS. However, the true mechanism remains unknown. Despite 
the occurrence of BBS, it is still indicated to continue phototherapy in 
neonatal jaundice due to the innately toxic effects of excess conjugated 
bilirubin.42 
 
Small Molecule Activators 
A group of researchers, in 2019, looked at devising therapeutic 
measures for G6PD deficiency.44 They postulate that the use of small 
molecule activators of the enzyme can promote the activity of the 
enzyme in deficient patients. The primary principle behind this is 
protein-protein interactions (PPIs). PPIs are the reason for the immense 
signalling networks that are present for normal cellular functions. These 
molecular interactions together are termed as the interactome, and 
intervening in these is prime for modifying disease pathogenesis. Apart 
from signalling events, the interactome comprises of interactions 
between the quaternary structure of proteins to modulate enzyme 
stability, activity and function.44 Hence the use of small molecules that 
target this aspect of the interactome is essential in enhancing 
enzymatic activity of G6PD.  
 
The primary cause of pathogenicity in G6PD deficient individuals are 
mutations that affect the homodimer interface of the enzyme. This is 
because only the homodimer and homtetrameric forms of the enzyme 
are active and stable. Raub et al.,44 identified AG1, a small molecule 
activator, from a common pathogenic mutation of g6pdx. In order to 
develop a suitable therapeutic agent, the mechanism of the molecule, 
AG1, was studied by the group. They postulated that AG1 promoted 
G6PD dimerization. This was achieved by the bridging of two NADP+ 
binding sites. The C2-symmetric region of the G6PD homodimer is 
important for activation which is targeted by AG1.44 Due to the observed 
increase in activity of enzyme by AG1, it can be considered in the 
treatment of G6PD deficiency. This drug can also be used in the 
prevention of complications that arise as a consequence of the 
deficiency.45 However, it was observed that AG1 was not able to activate 
the enzyme in certain kinds of mutations. AG1 still is a novel class 
molecule that promotes activation in multiple pathogenic mutants.44 
 
Conclusion 
G6PD deficiency is a common enzymatic disorder that is inherited in an 
X-linked manner. Unlike other enzymatic disorders, G6PD is not rare; 
however, the majority of the population affected by the disease are 
asymptomatic, unless they inherit a severe mutant copy of the enzyme. 
Clinical features appear only after exposure to certain oxidative 
stressors which primarily include antimalarial drugs and fava beans. 
Diagnostic measures to detect the presence of G6PD deficiency include 
enzymatic activity detection and molecular analysis. Newer techniques 
have been formulated in the past few years that have demonstrated 
better efficacy in diagnosing the condition compared to existing 
techniques. Currently, there is no effective treatment for the deficiency, 
removal of the trigger is frequently all that is required. In certain cases, 
blood transfusion and haemodialysis may be necessary.  
 
Neonatal jaundice is a common early clinical manifestation of the 
disease. In the recent past, phototherapy has been used as a 
prophylactic measure for the management of the condition, along with 
avoidance of offending oxidative stressors. Various studies have been 
conducted to prove the effectiveness of the therapy and, although there 
are serious adverse reactions that have been reported due to 
phototherapy, its therapeutic effect outweighs the risk. 
Pharmacological modulation of the interactome is the future in drug 
discovery in this area. It is known that PPIs are important in enzyme 
stability and activation along with cell signalling. Hence, interventions 
acting on this target will likely prove immensely valuable in drug 
discovery, particularly for G6PD deficiency. Treatment strategies for the 
deficiency have seen significant advances in recent years, with small 
molecule activators demonstrating effective increases in enzymatic 
activity, albeit in in vitro studies. Further research needs to be 
conducted in this area to develop these small molecule activators for 
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